Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 May 2;68(5):e0159123.
doi: 10.1128/aac.01591-23. Epub 2024 Apr 5.

Prospective validation of a model-informed precision dosing tool for vancomycin treatment in neonates

Riste Kalamees  1 , Hiie Soeorg  1 , Mari-Liis Ilmoja  2 , Kadri Margus  3 , Irja Lutsar  1 , Tuuli Metsvaht  1   4
Affiliations

Prospective validation of a model-informed precision dosing tool for vancomycin treatment in neonates

Riste Kalamees et al. Antimicrob Agents Chemother. .

Abstract

We recruited 48 neonates (50 vancomycin treatment episodes) in a prospective study to validate a model-informed precision dosing (MIPD) software. The initial vancomycin dose was based on a population pharmacokinetic model and adjusted every 36-48 h. Compared with a historical control group of 53 neonates (65 episodes), the achievement of a target trough concentration of 10-15 mg/L improved from 37% in the study to 62% in the MIPD group (P = 0.01), with no difference in side effects.

Keywords: model-informed precision dosing; neonates; vancomycin.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Fig 1
Fig 1
Flowchart presenting the study group formation.
Fig 2
Fig 2
The violin plots and boxplots of the 24-h area under the time-concentration curve of vancomycin calculated based on (A) the first measured steady-state Ctrough (SS-Ctrough) and (B) all SS-Ctrough after adjusted doses in control (light gray) and study group (dark gray). The dashed lines show the target range of AUC/MIC 400–700 mg∙h/L.
See this image and copyright information in PMC

References

    1. Jacqz-Aigrain E, Zhao W, Sharland M, van den Anker JN. 2013. Use of antibacterial agents in the neonate: 50 years of experience with vancomycin administration. Semin Fetal Neonatal Med 18:28–34. doi:10.1016/j.siny.2012.10.003 - DOI - PubMed
    1. Ringenberg T, Robinson C, Meyers R, Degnan L, Shah P, Siu A, Sturgill M. 2015. Achievement of therapeutic vancomycin trough serum concentrations with empiric dosing in neonatal intensive care unit patients. Pediatr Infect Dis J 34:742–747. doi:10.1097/INF.0000000000000664 - DOI - PubMed
    1. Dersch-Mills D, Bengry T, Akierman A, Alshaikh B, Yusuf K. 2014. Assessment of initial vancomycin dosing in neonates. Paediatr Child Health 19:291. doi:10.1093/pch/19.6.291 - DOI - PMC - PubMed
    1. Frymoyer A, Stockmann C, Hersh AL, Goswami S, Keizer RJ. 2019. Individualized empiric vancomycin dosing in neonates using a model-based approach. J Pediatric Infect Dis Soc 8:97–104. doi:10.1093/jpids/pix109 - DOI - PubMed
    1. Abouelkheir M, Almohaizeie A, Almutairi A, Almuhisen S, Alqahtani S, Alsultan A. 2023. Evaluation of vancomycin individualized model-based dosing approach in neonates. Pediatr Neonatol 64:327–334. doi:10.1016/j.pedneo.2022.10.006 - DOI - PubMed

Publication types